Phase I
Two months after positive preliminary data showed sitravatinib in combination with Opdivo demonstrated some efficacy in treating patients with NSCLC, Mirati said it will reprioritize its R&D to focus.
Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics.
BMS is pushing forward with its internal IDO1 program and showing off early-stage data from its Phase I/IIa combination trial of Opdivo plus BMS-986205, an IDO1 inhibitor.
ALZ’s researchers continue to see hope in Biogen’s aducanumab.
Bluebird is making forays into the CAR-T immuno-oncology market, although it has yet to bring a product to market.
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
During a fireside chat at BIO in San Diego earlier this summer, Daniel Skovronsky confirmed Eli Lilly’s commitment to finding an effective therapy for ALZ’s disease.
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
PRESS RELEASES